CD40-activated B cells contribute to mesothelioma tumor regression

The Transcription Factor Fli-1 Modulates Marginal Zone and Follicular B Cell Development in Mice

(2014) X. K. Zhang et al.   JOURNAL OF IMMUNOLOGY

B Cells Are Required for Optimal CD4+ and CD8+ T Cell Tumor Immunity: Therapeutic B Cell Depletion Enhances B16 Melanoma Growth in Mice

(2010) D. J. DiLillo et al.   JOURNAL OF IMMUNOLOGY

Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens

(2009) Sang-Ki Kim et al.   ANNALS OF HEMATOLOGY

Local effector failure in mesothelioma is not mediated by CD4+ CD25+ T-regulator cells

(2009) C. Jackaman et al.   EUROPEAN RESPIRATORY JOURNAL

Using CD40-activated B Cells to Efficiently Identify Epitopes of Tumor Antigens

(2009) Eisei Kondo et al.   JOURNAL OF IMMUNOTHERAPY

Deliberately provoking local inflammation drives tumors to become their own protective vaccine site

(2008) Connie Jackaman et al.   INTERNATIONAL IMMUNOLOGY

Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice

(2008) Juliana Hamzah et al.   JOURNAL OF CLINICAL INVESTIGATION